drugset / Trial / NCT00464165
Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period and to observe the percentage of abstinent subjects during a 40-week follow-up post treatment.
Timeline
- Start
- 2002-11
- Primary completion
- 2003-10
- Completion
- 2003-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimonabant | Small molecule | 5 mg | Oral |
| Subject | Rimonabant | Small molecule | 20 mg | Oral |
Indications
No indication recorded.